-
1
-
-
84864283226
-
SGLT2 inhibition in diabetes mellitus: Rationale and clinical prospects
-
Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol 2012; 8:495-502
-
(2012)
Nat Rev Endocrinol
, vol.8
, pp. 495-502
-
-
Ferrannini, E.1
Solini, A.2
-
2
-
-
84962339296
-
Euglycemic diabetic ketoacidosis: A potential complication of treatment with sodium-glucose cotransporter 2 inhibition
-
Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 2015; 38:1687-1693
-
(2015)
Diabetes Care
, vol.38
, pp. 1687-1693
-
-
Peters, A.L.1
Buschur, E.O.2
Buse, J.B.3
Cohan, P.4
Diner, J.C.5
Hirsch, I.B.6
-
3
-
-
84959366596
-
Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: Possible mechanism and contributing factors
-
Ogawa W, Sakaguchi K. Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors. J Diabetes Investig 2016; 7:135-138
-
(2016)
J Diabetes Investig
, vol.7
, pp. 135-138
-
-
Ogawa, W.1
Sakaguchi, K.2
-
5
-
-
84885954870
-
Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: A randomised, double-blind, placebo-controlled, phase 3 trial
-
Roden M, Weng J, Eilbracht J, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 2013; 1:208-219
-
(2013)
Lancet Diabetes Endocrinol
, vol.1
, pp. 208-219
-
-
Roden, M.1
Weng, J.2
Eilbracht, J.3
-
6
-
-
84888059660
-
Efficacy and safety of canagliflozin inpatients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: A randomised trial
-
Wilding JPH, Charpentier G, Hollander P, et al. Efficacy and safety of canagliflozin inpatients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract 2013; 67:1267-1282
-
(2013)
Int J Clin Pract
, vol.67
, pp. 1267-1282
-
-
Wilding, J.P.H.1
Charpentier, G.2
Hollander, P.3
-
7
-
-
84903511385
-
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes
-
Rosenstock J, Jelaska A, Frappin G, et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care 2014; 37:1815-1823
-
(2014)
Diabetes Care
, vol.37
, pp. 1815-1823
-
-
Rosenstock, J.1
Jelaska, A.2
Frappin, G.3
-
8
-
-
84964240560
-
Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes
-
Bode B, Stenlof K, Harris S, et al. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes. Diabetes Obes Metab 2015; 17:294-303
-
(2015)
Diabetes Obes Metab
, vol.17
, pp. 294-303
-
-
Bode, B.1
Stenlof, K.2
Harris, S.3
-
9
-
-
84944800184
-
Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
-
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117-2128
-
(2015)
N Engl J Med
, vol.373
, pp. 2117-2128
-
-
Zinman, B.1
Wanner, C.2
Lachin, J.M.3
-
10
-
-
84885952950
-
Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled trial
-
Häring HU, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2013; 36:3396-3404
-
(2013)
Diabetes Care
, vol.36
, pp. 3396-3404
-
-
Häring, H.U.1
Merker, L.2
Seewaldt-Becker, E.3
-
11
-
-
84887997289
-
Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: A randomised trial
-
Lavalle-González FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 2013; 56:2582-2592
-
(2013)
Diabetologia
, vol.56
, pp. 2582-2592
-
-
Lavalle-González, F.J.1
Januszewicz, A.2
Davidson, J.3
-
12
-
-
84901455931
-
Empagliflozin as add-on to metformin in patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled trial
-
Häring HU, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2014; 37:1650-1659
-
(2014)
Diabetes Care
, vol.37
, pp. 1650-1659
-
-
Häring, H.U.1
Merker, L.2
Seewaldt-Becker, E.3
-
13
-
-
84892477577
-
Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: A 24-week, randomized, placebo-controlled trial
-
Kovacs CS, Seshiah V, Swallow R, et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 2014; 16:147-158
-
(2014)
Diabetes Obes Metab
, vol.16
, pp. 147-158
-
-
Kovacs, C.S.1
Seshiah, V.2
Swallow, R.3
-
14
-
-
84942294658
-
Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: A 78-week randomized, double-blind, placebo-controlled trial
-
Rosenstock J, Jelaska A, Zeller C, Kim G, Broedl UC, Woerle HJ. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2015; 17:936-948
-
(2015)
Diabetes Obes Metab
, vol.17
, pp. 936-948
-
-
Rosenstock, J.1
Jelaska, A.2
Zeller, C.3
Kim, G.4
Broedl, U.C.5
Woerle, H.J.6
-
15
-
-
84962439093
-
Euglycemic diabetic ketoacidosis: A predictable, detectable, and preventable safety concern with SGLT2 inhibitors
-
Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 2015; 38: 1638-1642
-
(2015)
Diabetes Care
, vol.38
, pp. 1638-1642
-
-
Rosenstock, J.1
Ferrannini, E.2
|